Iran Escalated, Skipped Talks, and the Market Priced It In Immediately

The Iran trade you thought was over came back on Monday.

The U.S. seized an Iranian cargo ship, Tehran skipped peace talks, oil jumped 6.9% to $89.61, and the ceasefire deadline hanging over Wednesday added to the pressure. 

The S&P fell 0.3%, the Russell 2000 hit a new all-time high, and Trump's psychedelic executive order was the day's biggest surprise catalyst. Today's Closing Bell has everything.

Many are wondering why so many countries are frantically buying gold right now.

The truth is that this is just the beginning of a much larger story...

One that could send gold soaring to even bigger highs in the coming months. But the best way to cash in on gold's upside potential might surprise you.

One firm says this stock (less than $50) could be the best way to get started.

Find Out How to Profit From Gold’s Next Move

Stocks retreated Monday as U.S.-Iran tensions escalated over the weekend: the U.S. seized an Iranian-flagged cargo ship in the Gulf of Oman, Iran skipped peace talks in Pakistan, and WTI crude jumped 6.9% back to $89.61, reversing a portion of Friday's 10% drop and putting the ceasefire that expires Wednesday back in question.  

The session's biggest surprise came from Trump's Saturday executive order directing the FDA to use the Commissioner's National Priority Vouchers to cut psychedelic drug review timelines from 6-10 months down to 1-2 months, driving AtaiBeckley up 22% and GH Research up 17% in their best single-session moves in years.

Blue Owl Capital (NYSE: OWL) just acquired Sila Realty Trust for $2.4 billion in cash. The deal brings 137 healthcare properties across 65 U.S. markets under Blue Owl's roof.

Medical offices. Clinics. Specialized facilities. The kind of buildings where demand is driven by biology, not software cycles. Blue Owl has taken hits recently.

This deal says the company knows exactly where it wants to go next.

Software Burned, Healthcare Heals

Blue Owl and its peers loaded up on software and tech-adjacent lending during the boom years. Then AI arrived and threatened the pricing power of every software company on which those loans were built.

The result was painful. This acquisition is the course correction.

Healthcare real estate does not care about AI disruption. Patients show up. Rent gets paid. You cannot automate away a doctor's office, and Blue Owl is betting heavily on that simplicity.

The Fastest Growing Part of the Business

Blue Owl's real assets division added $17 billion last year, growing faster than any other segment. This deal pushes that division further ahead.

The company is deliberately shifting its center of gravity toward physical assets with predictable income.

That trajectory tells your entire story about where Blue Owl sees its future. Less exposure to volatile tech lending. More exposure to buildings that generate rent regardless of what markets do.

You respect a company that takes a beating, learns the lesson, and then puts $2.4 billion behind the answer. Blue Owl just did exactly that.

Arcus Biosciences (NASDAQ: RCUS) just halted its most important clinical trial after an independent review committee determined the lung cancer study was unlikely to succeed.

The Phase 3 STAR-121 trial tested a combination therapy against the current standard of care for first-line metastatic lung cancer. It did not work.

Days later, partner Gilead Sciences decided not to continue its option rights beyond July, effectively stepping back from the collaboration that anchored Arcus's entire pipeline strategy.

One Trial, One Partner, Both Gone

Arcus designed its business around this Gilead partnership and the lung cancer program at its center. Losing the trial is painful.

Losing the partner's continued commitment compounds that pain into something existential.

You build a biotech company on two pillars. The lead drug and the deep-pocketed partner funding it. Arcus just watched both crack at the same time.

What Survives

Arcus retains full rights to Casdatifan and its development program. That asset now carries the weight of the entire company's future.

Whether it is enough to rebuild the story around depends on what the data shows and how fast Arcus moves.

You rarely see a biotech lose its lead program and its anchor partnership in the same announcement. Arcus has to prove very quickly that what remains is worth believing in.

Here's how a new stock fore casting AI created in Baltimore, Maryland could help you grow your portfolio dramatically over the next year... even if you've NEVER used any AI before.

Hi, my name is Keith Kaplan. I'm a software engineer who creates trading tools for 100,000 people.

Those folks use my firm's work to track $30 billion of investment capital. Today, with the help of a former Air Force nuclear missile coder…

I recently released a new AI tool… that can forecast U.S. stock prices with remarkable results, to the cent, up to 21 days in advance. But instead of reserving it for my private subscribers…

I'm letting you try it yourself now, for free

Adobe Inc (NASDAQ: ADBE) just launched CX Enterprise, a new AI-powered suite designed to help large businesses automate and personalize how they interact with customers.

The platform uses AI agents to manage digital marketing functions that previously required teams of people.

Adobe is also partnering with Amazon, Microsoft, Anthropic, OpenAI, and Nvidia to make the system work across different platforms.

Here is the twist. Some of those partners are the same companies building tools that directly threaten Adobe's core business.

The Threat Is Real, and Adobe Knows It

AI startups and large language model companies are rapidly building tools that can design, create content, and manage marketing workflows.

Adobe's response is not to hide behind its existing products. It is to move fast and integrate the same AI technology into its own platform before customers decide they do not need Adobe anymore.

Adobe chose to partner with Anthropic and OpenAI rather than compete against them in isolation. That is either brilliant pragmatism or an admission that building everything alone is no longer possible.

The Identity Question

Adobe built a $200 billion business on creative software. Now the company is pivoting toward enterprise AI and automated marketing at a moment when its creative tools face unprecedented competition.

Your understanding of Adobe has to evolve alongside the company itself. It is no longer just the brand that powers designers.

It is becoming the platform that powers how entire businesses communicate with customers.

👉 Click here to get our closing report to your cell for free!

Avis Budget [CAR] $605.39 (+22.58%)

Avis continues its short-squeeze-driven surge, now up over 100% in recent weeks, driven by the Strait of Hormuz reopening, reducing travel disruption fears, and renewed investor interest following its Waymo partnership announcement.

The stock trades well above consensus analyst targets, but short interest remains elevated, sustaining momentum as bears cover.

The ceasefire progress this week reinforced the travel recovery thesis that has been the core driver since April.

MaxLinear [MXL] $31.90 (+21.43%)

MaxLinear designs semiconductor chips for optical networking and broadband infrastructure, and is a direct beneficiary of the chip sector's 14-day winning streak, which has pushed the PHLX Semiconductor Index up 33.8% over that stretch.

AI data center connectivity demand is accelerating orders for MXL's optical networking silicon, and the stock ran on volume at 5.06x average with a Buy consensus and no negative news.

This is pure sector momentum on a fundamentally sound name.

GH Research [GHRS] $21.44 (+16.90%)

GH Research is developing mebufotenin (HRS-004), a short-acting psychedelic delivered by inhalation for treatment-resistant depression, and holds an FDA breakthrough therapy designation that makes it a direct beneficiary of Trump's Saturday executive order.

The EO cuts the standard 6-10 month FDA review to 1-2 months via priority review vouchers. Jefferies called the order an "official stamp of validation" for the class and named GHRS among the primary beneficiaries.

Agios Pharmaceuticals [AGIO] $27.07 (-22.98%)

Agios reported that its Phase 3 ACTIVATE-T trial of tebapivat in transfusion-dependent thalassemia failed to meet its primary endpoint, with the drug showing no statistically significant improvement over placebo in reducing transfusion burden.

The failure removes one of the company's key near-term commercial catalysts and sent the stock down 23% on volume nearly 6x average. 

Fermi Inc. [FRMI] $5.37 (-18.05%)

CEO Toby Neugebauer resigned Friday, and CFO Miles Everson resigned Sunday, with both moves disclosed in a Monday regulatory filing.

Fermi is building what it aims to be one of the world's largest data center campuses in Amarillo, Texas, but currently has no anchor tenant signed, no revenue, and no permanent leadership.

Stifel analysts said the management change could ultimately improve credibility with institutional investors, but the stock priced the leadership vacuum immediately.

Rayonier Advanced Materials [RYAM] $9.09 (-11.14%) 

Rayonier Advanced Materials produces specialty cellulose and high-purity dissolving pulp for industrial and pharmaceutical applications.

The stock reversed sharply on volume at 6.94x average despite holding a Strong Buy consensus, suggesting institutional profit-taking after a momentum-driven run.

The process industries sector faced rotation pressure today as oil's return to $89 increased input cost concerns for industrial manufacturers relying on energy-intensive production processes.

Hedge fund legend Ray Dalio has been clear: when your portfolio drops, one asset does very well. Physical gold.

Right now, Wall Street is sitting on the highest level of borrowed money ever recorded — higher than before the Dot-Com crash, higher than before the 2008 financial crisis.

When that debt unwinds, it won't just hit hedge funds. It'll hit the Apple, Microsoft, and S&P 500 index funds sitting inside your 401(k).

There's a legal, IRS-approved way to move part of your retirement into physical gold today. A free guide explains the exact steps.

Get the Free 2026 Gold IRA Guide

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.